Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation

Hum Mol Genet. 2011 Dec 15;20(24):4947-77. doi: 10.1093/hmg/ddr432. Epub 2011 Sep 23.

Abstract

A functional genetic screen using loss-of-function and gain-of-function alleles was performed to identify modifiers of tau-induced neurotoxicity using the 2N/4R (full-length) isoform of wild-type human tau expressed in the fly retina. We previously reported eye pigment mutations, which create dysfunctional lysosomes, as potent modifiers; here, we report 37 additional genes identified from ∼1900 genes screened, including the kinases shaggy/GSK-3beta, par-1/MARK, CamKI and Mekk1. Tau acts synergistically with Mekk1 and p38 to down-regulate extracellular regulated kinase activity, with a corresponding decrease in AT8 immunoreactivity (pS202/T205), suggesting that tau can participate in signaling pathways to regulate its own kinases. Modifiers showed poor correlation with tau phosphorylation (using the AT8, 12E8 and AT270 epitopes); moreover, tested suppressors of wild-type tau were equally effective in suppressing toxicity of a phosphorylation-resistant S11A tau construct, demonstrating that changes in tau phosphorylation state are not required to suppress or enhance its toxicity. Genes related to autophagy, the cell cycle, RNA-associated proteins and chromatin-binding proteins constitute a large percentage of identified modifiers. Other functional categories identified include mitochondrial proteins, lipid trafficking, Golgi proteins, kinesins and dynein and the Hsp70/Hsp90-organizing protein (Hop). Network analysis uncovered several other genes highly associated with the functional modifiers, including genes related to the PI3K, Notch, BMP/TGF-β and Hedgehog pathways, and nuclear trafficking. Activity of GSK-3β is strongly upregulated due to TDP-43 expression, and reduced GSK-3β dosage is also a common suppressor of Aβ42 and TDP-43 toxicity. These findings suggest therapeutic targets other than mitigation of tau phosphorylation.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyloid beta-Peptides / toxicity
  • Animals
  • Computational Biology
  • DNA-Binding Proteins / toxicity
  • Drosophila melanogaster / drug effects
  • Drosophila melanogaster / enzymology
  • Drosophila melanogaster / genetics*
  • Enzyme Activation / drug effects
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Eye / drug effects
  • Eye / pathology
  • Gene Regulatory Networks / genetics*
  • Genes, Modifier / genetics*
  • Genes, Suppressor
  • Genetic Testing*
  • Genomics / methods*
  • Glycogen Synthase Kinase 3 / metabolism
  • Glycogen Synthase Kinase 3 beta
  • Humans
  • MAP Kinase Kinase Kinase 1 / metabolism
  • Mutant Proteins / toxicity
  • Neurotoxins / toxicity
  • Peptides / toxicity
  • Phosphorylation / drug effects
  • Tauopathies / genetics*
  • p38 Mitogen-Activated Protein Kinases / metabolism
  • tau Proteins / metabolism*
  • tau Proteins / toxicity

Substances

  • Amyloid beta-Peptides
  • DNA-Binding Proteins
  • Mutant Proteins
  • Neurotoxins
  • Peptides
  • tau Proteins
  • polyglutamine
  • GSK3B protein, human
  • Glycogen Synthase Kinase 3 beta
  • Extracellular Signal-Regulated MAP Kinases
  • p38 Mitogen-Activated Protein Kinases
  • MAP Kinase Kinase Kinase 1
  • Glycogen Synthase Kinase 3